| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms |
| 12 Nov 2026 | 10-Q |
| 27 Oct 2026 |
Form 3: Alland Leila, Chief Medical Officer
No securities owned |
| 27 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
Seasoned oncology executive brings extensive clinical development expertise and a track record of advancing innovative cancer therapies |
| 22 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 22, 2026, Cardiff Oncology, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). A total of 48,084,246 shares of common stock, constituting a quorum, were represented in person or by valid pro... |
| 14 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
| 26 Aug 2026 | DEFA14A |
| 26 Aug 2026 | DEF 14A |
| 14 Aug 2026 | PRE 14A |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC |
| 11 Aug 2026 | 10-Q |
| 27 Jul 2026 | SCHEDULE 13G/A |
| 21 Jul 2026 | S-8 |
| 16 Jul 2026 |
Form 4: Pace Gary W, Director
Bought 687,285 shares ($1M) · Acquired 687,285 Common Stock Purchase Warrant (Open Market Purchase) |
| 16 Jul 2026 |
Form 4: Mohindru Mani, Director
Bought 34,364 shares ($50K) · Acquired 34,364 Common Stock Purchase Warrant (Open Market Purchase) |
| 16 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of July 14, 2026, between Cardiff Oncology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its ... |
| 16 Jul 2026 | 424B5 |
| 22 Jun 2026 |
Form 4: Mohindru Mani, Director
Bought 24,703 shares ($29.9K) |
| 22 Jun 2026 |
Form 4: Pace Gary W, Director
Bought 30,000 shares ($36.6K) |
Loading...